drugset / Trial / NCT03681470

Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color

NCT03681470

Phase 4 Completed 20 enrolled Icahn School of Medicine at Mount Sinai
NaSingle-groupOpen-labelTreatment

Summary

Acne vulgaris is a common skin disease characterized by inflammatory papules, pustules, and comedones that is prevalent in men and women of color. Research has demonstrated that Aczone ® (dapsone) gel, 7.5% used once daily is effective, safe, and well-tolerated for the treatment of acne in both men and women; however, limited data is available regarding its efficacy and safety in skin of color (SOC). The current study aims to investigate the therapeutic impact of Aczone gel 7.5% in SOC males and females ages 18 and older with acne vulgaris. The study will also evaluate the impact of Aczone ® gel on hyperpigmentation and PIH of the face.

Timeline

Start
2019-04-09
Primary completion
2021-05-06
Completion
2021-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapsone Small molecule 7.5 %

Indications